1. Accueil Zonebourse
  2. Actions
  3. France
  4. Euronext Paris
  5. LYSOGENE
  6. Actualités
  7. Autres langues
    LYS   FR0013233475

LYSOGENE

(LYS)
  Rapport
Temps réel Euronext Paris  -  16/05 17:35:15
0.6600 EUR   -2.94%
28/04LYSOGENE : Chiffre d'affaires 1er trimestre
CO
21/04LYSOGENE : porté par des résultats précliniques positifs
CF
21/04La thérapie génique de Lysogene montre un sauvetage à long terme du syndrome du X fragile dans un modèle de souris
MT
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusDérivésFonds 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur LYSOGENE
28/04LYSOGENE : Quarterly financial reporting / First quarter financial report
21/04Lysogene's Gene Therapy Shows Long-Term Rescue of Fragile X Syndrome in Mouse Model
21/04LYSOGENE : Inside Information / Other news releases
20/04LYSOGENE : Terms of availability of a registration document or its updates
31/03Lysogene S.A. Reports Earnings Results for the Full Year Ended December 31, 2021
24/02Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance Phase 2/3 Cli..
11/02Lysogene Reports Additional Positive Biomarker Data With LYS-SAF302 and Favorable Safet..
07/02Lysogene Jumps 14% On New Chief Medical Officer's Appointment
07/02Lysogene Doses First Patient in Early-Stage Rare Disease Study in France; Shares Up 7%
07/02Lysogene S.A. Provides Medical Update
27/01LYSOGENE : Inside Information / Information on annual revenues
13/01Lysogene Restores Global Commercial Rights of Rare Disease Treatment
13/01Lysogene Announces Termination of License Agreement With Sarepta for LYS-SAF302 Program..
2021European stocks close lower in thin holiday trade
2021EN DIRECTO DESDE LOS MERCADOS : ACS, Airbus, Acerinox, Banco de Sabadell, HSBC, Icade, Cos..
2021Sesión reducida antes de Navidad
2021Lysogene S.A. announced that it expects to receive €15 million in funding from Eur..
2021Lysogene Awards Innovation Passport by the UK MHRA for the GM1 Gangliosidosis Program
2021Lysogene S.A. Secures EUR 4.3 Million Non-Dilutive Financing from Bpifrance to Support ..
2021Lysogene S.A. announced that it has received ?4.3 million in funding from Bpifrance Inv..
2021Lysogene S.A. Reports Earnings Results for the First Half 2021
2021GLOBAL MARKETS LIVE : Sanofi, Walt Disney, Roche, Flatexdegiro, KBC Group...
2021LYSOGENE : Announces First Patient in the United States Dosed with LYS-GM101 Investigation..
2021LYSOGENE : Doses First Patient with Investigational Gene Therapy in US to Treat Genetic Di..
2021Lysogene Announces First Patient in the United States Dosed with LYS-GM101 Investigatio..
2021Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conectus for a ..
2021GLOBAL MARKETS LIVE : Tesla, BT Group, GameStop, Alibaba, Boeing...
2021Vuelve el cóctel de bancos centrales e inflación
2021
2021Lysogene Announces First Patient Dosed with LYS-GM101 Investigational Gene Therapy for ..
2021LYSOGENE : Meeting Notice of the Annual Ordinary and Extraordinary General Meeting to be h..
2021Lysogene Announces Phase 3 Gene Therapy Platform Company Targeting Central Nervous Syst..
2021EN DIRECTO DESDE LOS MERCADOS : Nokia, Apple, Facebook, Logitech, Total, STMicro, Airbus, ..
2021LYSOGENE : 2020 annual report of liquidity contract
2021Lysogene S.A. Reports Earnings Results for the Year Ended 31 December 2020
2021LYSOGENE : Reports its Cash Position as of 31 December 2020
2021LYSOGENE : Reports LYS-SAF302 Biomarker Data Presented at the WORLDSymposium™ 2021
2021Lysogene Reports LYS-SAF302 Biomarker Data Presented at the WORLDSymposium 2021
2021LYSOGENE : Up 13% After Getting Trial Clearance From US FDA For Gene Therapy
2021LYSOGENE : Receives FDA Clearance of Investigational New Drug Application to Initiate the ..
2021Lysogene S.A. Receives FDA Clearance of Investigational New Drug Application to Initiat..
2021LYSOGENE : Gets $6.1 Million In Financing From France's BRED
2021LYSOGENE : Secures €5 million in Non-Dilutive Financing
2021Lysogene Secures €5 Million in Non-Dilutive Financing
2021LYSOGENE : Announces Its Financial Calendar For 2021
2021LYSOGENE : Half-Year Report on the Liquidity Contract Signed by Lysogene with Kepler Cheuv..
2021LYSOGENE : Up 8% After Receiving Approval For Clinical Trial in UK
2021LYSOGENE : Receives MHRA and Research Ethics Committee Approvals to Initiate the Gene Ther..
2021Lysogene Receives MHRA and Research Ethics Committee Approvals to Initiate the Gene The..
2020LYSOGENE : Releases Positive Biomarker Data for LYS-SAF302 in Central Nervous System Disor..
2020LYSOGENE : Reports Positive Biomarker Data With LYS-SAF302
2020Lysogene Reports Positive Biomarker Data With LYS-SAF302
2020LYSOGENE : Announces a Change in the Organization of KGA, Minority Shareholder of Lysogene..
2020LYSOGENE : Reports its Cash Position as of 30 September 2020
2020LYSOGENE : provides update on the AAVance Clinical Trial Evaluating LYS-SAF302 in Patients..
2020LYSOGENE : Provides Update on the AAVance Clinical Trial Evaluating LYS-SAF302 in Patients..
2020Lysogene Provides Update on the AAVance Clinical Trial Evaluating Lys-Saf302 in Patient..
2020LYSOGENE : Reports First Half 2020 Financial Results and Provides Operational Update
2020Lysogene Reports Earnings Results for the First Half Ended June 30, 2020
2020LYSOGENE : Reports First Half 2020 Financial Results and Provides Operational Update
2020LYSOGENE : First Half 2020 Business Update
2020LYSOGENE : Announces a Research Collaboration With the Weizmann Institute of Science
2020Lysogene Announces a Research Collaboration with the Yeda Research and Development Co L..
2020LYSOGENE : Releases the Results From June 26, 2020 Ordinary Annual and Extraordinary Gener..
2020LYSOGENE : announces important updates on AAVance phase 2/3 clinical trial with LYS-SAF302..
2020Lysogene Announces Important Updates on AAVance Phase 2/3 Clinical Trial with LYS-SAF30..
2020LYSOGENE : NOVASEP and LYSOGENE Announce their New Collaboration for Development and Produ..
2020Novasep and Lysogene Announce Their New Collaboration for Development and Production of..
2020LYSOGENE : Annual Ordinary and Extraordinary General Meeting of 26 June 2020
2020LYSOGENE : Announces Presentations at Upcoming Meetings
2020LYSOGENE : Kepler Cheuvreux Initiates Coverage of Lysogene
2020LYSOGENE : Announces Filing of 2019 Universal Registration Document
2020LYSOGENE : Reports Its Cash Position as of 31 March 2020
2020Lysogene S.A. Reports Consolidated Earnings Results for the Year Ended 31 December 2019
2020LYSOGENE : Reports Full Year 2019 Financial Results and Provides Operational Update
1  2Suiv.
Prochain événement sur LYSOGENE